Navigation Links
GenVec Regains Compliance with NASDAQ Listing Requirements
Date:5/5/2011

GAITHERSBURG, Md., May 5, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVCD) today announced that on May 4, 2011, the Company received a letter from The NASDAQ Stock Market ("NASDAQ") advising that it had regained compliance with NASDAQ's minimum bid price listing requirements.

GenVec had received a notice of deficiency on May 12, 2010 stating that the Company was not in compliance with NASDAQ Marketplace Rules because the bid price of the Company's common stock had closed below the required minimum $1.00 per share for the previous 30 consecutive business days.

The letter received from NASDAQ on May 4, 2011 stated that GenVec's common stock had closed above the $1.00 minimum bid price for 10 consecutive business days and the Company had regained compliance with the minimum bid price listing requirement. NASDAQ advised that the matter is now closed.

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Investor and Media Contact:
GenVec, Inc.
Douglas J. Swirsky
(240) 632-5510
dswirsky@genvec.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
Breaking Biology Technology:
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/24/2017)... NEW YORK , Jan. 24, 2017 /PRNewswire/ ... market study of the laboratory use of nuclear ... of 363 experienced end-users and profiled current practices, ... three years, as well as growth and opportunities. ... NMR, Instrument suppliers, NMR instruments, needs and innovation ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric ... CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... security for both public and private sectors. Continue ... ...
Breaking Biology News(10 mins):